Literature DB >> 15521982

Molecular delineation of deletions on 2q37.3 in three cases with an Albright hereditary osteodystrophy-like phenotype.

A E Shrimpton1, B R Braddock, L L Thomson, C K Stein, J J Hoo.   

Abstract

A minority of the reported cases of terminal 2q37 deletion clinically resemble Albright hereditary osteodystrophy (AHO)/pseudopseudohypoparathyroidism and have only mild-to-moderate mental retardation. Our molecular and cytogenetic fluorescence in situ hybridization (FISH) findings on an additional three patients further reduce the size of the minimal critical region deleted in this syndrome to about 3 Mb. This region includes the G-protein-coupled receptor 35 (GPR35), glypican 1 (GPC1), and serine/threonine protein kinase 25 (STK25) genes on 2q37.3. We have further defined several polymorphic variants within the coding region and flanking regions of GPR35 gene, which could potentially be useful for rapid detection of GPR35 gene deletion. We postulate that the absence of GPR35 may, at least partly, account for the phenotypic resemblance to the AHO. We also believe that the deletion of GPR35 could be responsible for the entity brachydactyly mental retardation syndrome (OMIM #600430), which was coined based on the above minority of patients with terminal 2q37 deletion. We recommend that every patient with AHO phenotype should undergo 2q subtelomeric FISH screen and subsequently a molecular study on the GPR35 gene. GPC1 and/or STK25 haploinsufficiency may also contribute to the AHO-like phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15521982     DOI: 10.1111/j.1399-0004.2004.00363.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  20 in total

1.  A genome-wide scan for genes involved in primary vesicoureteric reflux.

Authors:  H Kelly; C M Molony; J M Darlow; M E Pirker; A Yoneda; A J Green; P Puri; D E Barton
Journal:  J Med Genet       Date:  2007-07-27       Impact factor: 6.318

2.  Crucial positively charged residues for ligand activation of the GPR35 receptor.

Authors:  Pingwei Zhao; Tom R Lane; Helen G L Gao; Dow P Hurst; Evangelia Kotsikorou; Long Le; Eugen Brailoiu; Patricia H Reggio; Mary E Abood
Journal:  J Biol Chem       Date:  2013-12-17       Impact factor: 5.157

3.  High-throughput identification and characterization of novel, species-selective GPR35 agonists.

Authors:  Zaynab Neetoo-Isseljee; Amanda E MacKenzie; Craig Southern; Jeff Jerman; Edward G McIver; Nicholas Harries; Debra L Taylor; Graeme Milligan
Journal:  J Pharmacol Exp Ther       Date:  2012-12-21       Impact factor: 4.030

4.  Structure-activity relationships of benzothiazole GPR35 antagonists.

Authors:  Manahil M Abdalhameed; Pingwei Zhao; Dow P Hurst; Patricia H Reggio; Mary E Abood; Mitchell P Croatt
Journal:  Bioorg Med Chem Lett       Date:  2016-12-05       Impact factor: 2.823

5.  WDL-RF: predicting bioactivities of ligand molecules acting with G protein-coupled receptors by combining weighted deep learning and random forest.

Authors:  Jiansheng Wu; Qiuming Zhang; Weijian Wu; Tao Pang; Haifeng Hu; Wallace K B Chan; Xiaoyan Ke; Yang Zhang
Journal:  Bioinformatics       Date:  2018-07-01       Impact factor: 6.937

6.  Brief report: peculiar evolution of autistic behaviors in two unrelated children with brachidactyly-mental retardation syndrome.

Authors:  Luigi Mazzone; Lia Vassena; Liliana Ruta; Diego Mugno; Ornella Galesi; Marco Fichera
Journal:  J Autism Dev Disord       Date:  2012-10

7.  Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity.

Authors:  Pingwei Zhao; Haleli Sharir; Ankur Kapur; Alan Cowan; Ellen B Geller; Martin W Adler; Herbert H Seltzman; Patricia H Reggio; Susanne Heynen-Genel; Michelle Sauer; Thomas D Y Chung; Yushi Bai; Wei Chen; Marc G Caron; Larry S Barak; Mary E Abood
Journal:  Mol Pharmacol       Date:  2010-07-22       Impact factor: 4.436

8.  Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.

Authors:  Stephen R Williams; Micheala A Aldred; Vazken M Der Kaloustian; Fahed Halal; Gordon Gowans; D Ross McLeod; Sara Zondag; Helga V Toriello; R Ellen Magenis; Sarah H Elsea
Journal:  Am J Hum Genet       Date:  2010-08-13       Impact factor: 11.025

9.  Effect of L-tyrosine in vitro and in vivo on energy metabolism parameters in brain and liver of young rats.

Authors:  Gabriela K Ferreira; Giselli Scaini; Milena Carvalho-Silva; Lara M Gomes; Lislaine S Borges; Júlia S Vieira; Larissa S Constantino; Gustavo C Ferreira; Patrícia F Schuck; Emilio L Streck
Journal:  Neurotox Res       Date:  2012-07-31       Impact factor: 3.911

10.  The 2q37-deletion syndrome: an update of the clinical spectrum including overweight, brachydactyly and behavioural features in 14 new patients.

Authors:  Camille Leroy; Emilie Landais; Sylvain Briault; Albert David; Olivier Tassy; Nicolas Gruchy; Bruno Delobel; Marie-José Grégoire; Bruno Leheup; Laurence Taine; Didier Lacombe; Marie-Ange Delrue; Annick Toutain; Agathe Paubel; Francine Mugneret; Christel Thauvin-Robinet; Stéphanie Arpin; Cedric Le Caignec; Philippe Jonveaux; Mylène Beri; Nathalie Leporrier; Jacques Motte; Caroline Fiquet; Olivier Brichet; Monique Mozelle-Nivoix; Pascal Sabouraud; Nathalie Golovkine; Nathalie Bednarek; Dominique Gaillard; Martine Doco-Fenzy
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.